Reduction of cardiovascular events with the use of lipid-lowering medication in patients with familial hypercholesterolemia or severe primary hypercholesterolemia: A systematic review-Reference-Cited by-同舟云学术

Reduction of cardiovascular events with the use of lipid-lowering medication in patients with familial hypercholesterolemia or severe primary hypercholesterolemia: A systematic review

Published:2022-09 Issue:5 Volume:16 Page:562-573
ISSN:1933-2874
Container-title:Journal of Clinical Lipidology
language:en
Short-container-title:Journal of Clinical Lipidology

Author:

Masson Walter^ORCID,Corral Pablo,Barbagelata Leandro^ORCID,Lavalle-Cobo Augusto,Nogueira Juan P,Siniawski Daniel,Ray Kausik K

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Nutrition and Dietetics,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference37 articles.

1. Pharmacotherapy in Familial Hypercholesterolemia- current State and Emerging Paradigms;Kallapur;Trends Cardiovasc Med,2021

2. Past, present, and future of familial hypercholesterolemia management;Rocha;Methodist Debakey Cardiovasc J,2021

3. Epidemiology of familial hypercholesterolaemia: community and clinical;Vallejo-Vaz;Atherosclerosis,2018

4. The complex molecular genetics of familial hypercholesterolaemia;Berberich;Nat Rev Cardiol,2019

5. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials;Fulcher;Lancet.,2015

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia;JAMA Pediatrics;2024-03-01

2. Association of lipid-lowering drugs with osteoarthritis outcomes from a drug-target Mendelian randomization study;PLOS ONE;2024-02-28

3. Predicted deleterious variants in ABCA1, LPL, LPA and KIF6 are associated with statin response and adverse events in patients with familial hypercholesterolemia and disturb protein structure and stability;Pharmacogenetics and Genomics;2024-02-07

4. Adherence to pharmacotherapy: sine qua non for reducing cumulative risk of premature coronary disease in familial hypercholesterolemia;Current Opinion in Endocrinology, Diabetes & Obesity;2023-10-30

5. Association between lipid-lowering drugs and bone mineral density: A study employing drug-target Mendelian randomization;2023-06-27